WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
1. (WO1996007414) OINTMENT
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1996/007414    International Application No.:    PCT/JP1995/001670
Publication Date: 14.03.1996 International Filing Date: 23.08.1995
Chapter 2 Demand Filed:    27.02.1996    
A61K 9/06 (2006.01), A61K 47/06 (2006.01)
Applicants: NIPPON KAYAKU KABUSHIKI KAISHA [JP/JP]; 11-2, Fujimi 1-chome, Chiyoda-ku, Tokyo 102 (JP) (For All Designated States Except US).
OHTSUKI, Kazuo [JP/JP]; (JP) (For US Only).
KOMURO, Chikara [JP/JP]; (JP) (For US Only).
AOUDA, Yukio [JP/JP]; (JP) (For US Only).
IRIE, Yukio [JP/JP]; (JP) (For US Only)
Inventors: OHTSUKI, Kazuo; (JP).
KOMURO, Chikara; (JP).
AOUDA, Yukio; (JP).
IRIE, Yukio; (JP)
Priority Data:
6/236032 06.09.1994 JP
Abstract: front page image
(EN)An ointment which contains 9-[(1R, 2R, 3S)-2,3-bis(hydroxymethyl)cyclobutan-1-yl]guanine and an oleaginous base as the essential ingredient and wherein the guanine powder is homogeneously dispersed in the ointment base. An example thereof comprises 0.05 - 10 % of the guanine, 40 - 99.5 % of an oleaginous base, and if necessary a surfactant as an agent for imparting skin affinity and water as a base. The ointment is useful as an antiviral agent for topical application and exhibits an excellent therapeutic effect.
(FR)La présente invention concerne un onguent qui contient du 9-[(1R, 2R, 3S)-2,3-bis(hydroxyméthyl)cyclobutane-1-yl]guanine et d'une base oléagineuse comme principe actif essentiel, la poudre de guanine étant dispersée de façon homogène dans la base de l'onguent. Un exemple de cet onguent contient 0,05 % à 10 % de guanine, 40 % à 99,5 % de base oléagineuse, et, si nécessaire, un agent tensioactif conférant une affinité avec la peau, ainsi que de l'eau servant de base. Cet onguent, qui est utile comme agent antiviral en application locale, a un excellent effet thérapeutique.
Designated States: CN, KR, US.
European Patent Office (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)